BioMimetic Therapeutics, Inc. To Report 2011 Fourth Quarter And Year-End Financial Results On March 13

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the twelve months ended December 31, 2011, on Tuesday, March 13, 2012, after market close. The Company will host a conference call and audio webcast to discuss its fourth quarter and year-end financial results, product development programs and business activities at 4:30 p.m. EDT the same day.

The conference call may be accessed on March 13, 2012 by dialing (877) 224 - 4059 for the U.S. and Canada (passcode: 57985649). The international dial in number is (706) 902 - 2069, and the same passcode applies. Participants should dial in 10 minutes prior to the call.

A live webcast of the conference call will be available on the Investor Relations section of BioMimetic’s website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.

About BioMimetic Therapeutics

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.

BioMimetic received regulatory approval in 2009 and 2011 to market Augment in Canada, and in Australia for hindfoot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications. The Company also markets a bone graft substitute line of products for orthopedic indications called Augmatrix Biocomposite Bone Graft.

If you liked this article you might like

Who's Afraid of the Fiscal Cliff? Stocks Soar

Stocks to Watch: Lowe's, Cisco (Update 1)

4 Big Volume Gainers Under $10

3 Stocks Under $5 Making Large Moves to the Upside

5 Biotech Stocks Under $5 Blasting Off